[{"id":"e42e13ac-a207-4481-8490-407dcba3be1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06939452","created_at":"2025-09-07T01:21:18.589Z","updated_at":"2025-09-07T01:21:18.589Z","phase":"Phase 2","brief_title":"A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression","source_id_and_acronym":"NCT06939452","lead_sponsor":"Yongxu Jia","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • oxaliplatin • Andewei (benmelstobart) • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 06/07/2023","start_date":" 06/07/2023","primary_txt":" Primary completion: 06/07/2025","primary_completion_date":" 06/07/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-04-22"},{"id":"2d9a8f08-c565-475d-9d28-781aa1dd5529","acronym":"","url":"https://clinicaltrials.gov/study/NCT06662006","created_at":"2025-02-26T07:54:41.562Z","updated_at":"2025-02-26T07:54:41.562Z","phase":"Phase 2","brief_title":"Nal-IRI/5-FU/LV Chemotherapy Combined with PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT As Second-line Therapy in Metastatic Pancreatic Cancer Patients","source_id_and_acronym":"NCT06662006","lead_sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10 • IL17A • IFNA1 • IL1B","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL2 • IL10 • IL17A • IFNA1 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Focus V (anlotinib) • Andewei (benmelstobart) • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-10-28"},{"id":"14038a3a-bab1-4431-b313-a721b6553a56","acronym":"","url":"https://clinicaltrials.gov/study/NCT06116240","created_at":"2023-11-03T20:12:26.687Z","updated_at":"2024-07-02T16:35:30.413Z","phase":"Phase 1","brief_title":"A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT06116240","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • pemetrexed • Andewei (benmelstobart) • AL2846"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 09/02/2022","start_date":" 09/02/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-11-03"},{"id":"438be162-c70f-455b-9e16-39dac4b2d07b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05913089","created_at":"2023-06-22T19:11:31.734Z","updated_at":"2024-07-02T16:35:44.441Z","phase":"Phase 2","brief_title":"A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer","source_id_and_acronym":"NCT05913089","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Andewei (benmelstobart)"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 06/14/2023","start_date":" 06/14/2023","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-06-29"},{"id":"565d9c7a-c834-4faa-9d14-ac630ac812dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05645315","created_at":"2022-12-09T14:57:48.849Z","updated_at":"2024-07-02T16:35:59.356Z","phase":"Phase 1/2","brief_title":"Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05645315","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" EGFR • ALK • ROS1 • HAVCR2","pipe":" | ","alterations":" PD-L1 expression • ALK fusion • ALK mutation • ROS1 fusion • ROS1 mutation","tags":["EGFR • ALK • ROS1 • HAVCR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ALK fusion • ALK mutation • ROS1 fusion • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Andewei (benmelstobart) • TQB2618"],"overall_status":"Recruiting","enrollment":" Enrollment 127","initiation":"Initiation: 04/28/2022","start_date":" 04/28/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2022-12-09"},{"id":"6d57522c-e167-43b0-91dd-c86a02aeca40","acronym":"","url":"https://clinicaltrials.gov/study/NCT05346952","created_at":"2022-04-26T13:53:49.954Z","updated_at":"2024-07-02T16:36:11.496Z","phase":"Phase 3","brief_title":"A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).","source_id_and_acronym":"NCT05346952","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" ALK fusion • ROS1 fusion • ALK-ROS1 fusion","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK fusion • ROS1 fusion • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Focus V (anlotinib) • Tevimbra (tislelizumab-jsgr) • pemetrexed • Andewei (benmelstobart)"],"overall_status":"Recruiting","enrollment":" Enrollment 390","initiation":"Initiation: 01/25/2022","start_date":" 01/25/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-04-26"},{"id":"8ef7cbf2-dd6b-494a-b8bc-2ff9230a8ad0","acronym":"TQB2450-III-05","url":"https://clinicaltrials.gov/study/NCT04325763","created_at":"2021-01-18T20:57:17.125Z","updated_at":"2024-07-02T16:36:14.340Z","phase":"Phase 3","brief_title":"A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)","source_id_and_acronym":"NCT04325763 - TQB2450-III-05","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" PD-L1 • TMB","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Andewei (benmelstobart)"],"overall_status":"Recruiting","enrollment":" Enrollment 315","initiation":"Initiation: 05/27/2020","start_date":" 05/27/2020","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2022-03-31"},{"id":"3ffb0793-e1c4-44f6-8cca-f86eb1e16b31","acronym":"","url":"https://clinicaltrials.gov/study/NCT05145218","created_at":"2021-12-07T00:59:00.142Z","updated_at":"2024-07-02T16:36:19.720Z","phase":"Phase 3","brief_title":"A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer","source_id_and_acronym":"NCT05145218","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Focus V (anlotinib) • Andewei (benmelstobart)"],"overall_status":"Recruiting","enrollment":" Enrollment 405","initiation":"Initiation: 09/28/2021","start_date":" 09/28/2021","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2021-12-08"},{"id":"9ede2052-dcca-4922-b14c-3f70623bfbb4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05139082","created_at":"2021-12-01T15:53:48.087Z","updated_at":"2024-07-02T16:36:20.025Z","phase":"Phase 1/2","brief_title":"Study of CDK4/6 Inhibitor Combined With PD-L1 Monoclonal Antibody in the Treatment of PD-1/PD-L1 Resistance and Abnormal Cell Cycle Digestive System Tumors","source_id_and_acronym":"NCT05139082","lead_sponsor":"Peking University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Andewei (benmelstobart) • Saitanxin (culmerciclib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 11/24/2021","start_date":" 11/24/2021","primary_txt":" Primary completion: 10/01/2023","primary_completion_date":" 10/01/2023","study_txt":" Completion: 10/01/2023","study_completion_date":" 10/01/2023","last_update_posted":"2021-12-01"},{"id":"7ad64a8f-a1c1-4141-a640-1e451dbb4aa0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04964479","created_at":"2021-07-16T13:53:12.905Z","updated_at":"2024-07-02T16:36:26.053Z","phase":"Phase 3","brief_title":"A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)","source_id_and_acronym":"NCT04964479","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" EGFR mutation • ALK fusion","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Focus V (anlotinib) • Andewei (benmelstobart)"],"overall_status":"Recruiting","enrollment":" Enrollment 375","initiation":"Initiation: 08/06/2021","start_date":" 08/06/2021","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2021-08-20"},{"id":"30d7c5db-848a-429c-92d4-d193557d9ac4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04623333","created_at":"2021-01-19T20:34:49.171Z","updated_at":"2024-07-02T16:36:38.848Z","phase":"Phase 2","brief_title":"A Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical Cancer","source_id_and_acronym":"NCT04623333","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Andewei (benmelstobart)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 11/30/2020","start_date":" 11/30/2020","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 06/30/2023","study_completion_date":" 06/30/2023","last_update_posted":"2020-11-10"},{"id":"39b83c1b-a828-4de5-8e0b-d0f37ab6baad","acronym":"","url":"https://clinicaltrials.gov/study/NCT03855384","created_at":"2021-01-18T19:01:37.682Z","updated_at":"2024-07-02T16:36:54.138Z","phase":"Phase 3","brief_title":"Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck（R/M SCCHN）","source_id_and_acronym":"NCT03855384","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • 5-fluorouracil • Andewei (benmelstobart)"],"overall_status":"Unknown status","enrollment":" Enrollment 334","initiation":"Initiation: 06/11/2019","start_date":" 06/11/2019","primary_txt":" Primary completion: 12/31/2020","primary_completion_date":" 12/31/2020","study_txt":" Completion: 05/30/2021","study_completion_date":" 05/30/2021","last_update_posted":"2019-10-30"},{"id":"936af32e-f414-41ca-9777-943bff120db2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03910127","created_at":"2021-01-18T19:14:45.678Z","updated_at":"2024-07-02T16:36:54.127Z","phase":"Phase 1","brief_title":"Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）","source_id_and_acronym":"NCT03910127","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression • EGFR wild-type • ALK wild-type","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR wild-type • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Andewei (benmelstobart)"],"overall_status":"Unknown status","enrollment":" Enrollment 90","initiation":"Initiation: 06/11/2019","start_date":" 06/11/2019","primary_txt":" Primary completion: 12/31/2020","primary_completion_date":" 12/31/2020","study_txt":" Completion: 06/30/2021","study_completion_date":" 06/30/2021","last_update_posted":"2019-10-30"},{"id":"a018868e-d478-4841-91b8-a569848b5d0a","acronym":"TQB2450-Ib-07","url":"https://clinicaltrials.gov/study/NCT03855358","created_at":"2021-01-18T19:01:37.100Z","updated_at":"2024-07-02T16:36:54.142Z","phase":"Phase 1","brief_title":"A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC)","source_id_and_acronym":"NCT03855358 - TQB2450-Ib-07","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative • PGR expression","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Andewei (benmelstobart)"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 05/09/2019","start_date":" 05/09/2019","primary_txt":" Primary completion: 06/30/2020","primary_completion_date":" 06/30/2020","study_txt":" Completion: 12/30/2020","study_completion_date":" 12/30/2020","last_update_posted":"2019-10-30"}]